Calidi Biotherapeutics, Inc.

Calidi Biotherapeutics, Inc. has entered into a new lease agreement for office and laboratory space in San Diego, which is projected to result in annual savings of approximately $1.1 million. Concurrently, the company terminated its existing lease. The new lease is for 9,038 rentable square feet and has an initial term of 44 months, commencing October 1, 2026.

Calidi Biotherapeutics announced the appointment of Sandra Gurrola as VP Finance, Controller. In connection with her new role, the company's Compensation Committee and Board of Directors approved an inducement non-qualified stock option grant for 100,000 shares. The options have an exercise price of $0.15 and will vest over four years, with the first 25% vesting on July 6, 2027.

Calidi Biotherapeutics presented new data on its RedTail platform at the T-cell Engager Therapeutic Summit, demonstrating its approach to simultaneously activate T-cells and induce T-cell engager expression in the tumor microenvironment. The company highlighted the platform's potential to overcome historical limitations of T-cell engagers in solid tumors. Calidi expects to file an Investigational New Drug (IND) application for its lead candidate, CLD-401, by the end of 2026. Additionally, Calidi is developing CLD-501 targeting TROP2 and exploring other targets, while actively seeking strategic partnerships.

Calidi Biotherapeutics, Inc. announced the appointment of Dr. Corazon Sanders to its Board of Directors as a Class III director, effective June 17, 2026. Dr. Sanders, a biotechnology executive with over 30 years of experience, will also serve on the Audit Committee. Concurrently, the Board increased its size from five to six members, and Scott Leftwich was removed from the Audit Committee, though he remains a board member. The company issued a press release on June 23, 2026, to announce this appointment.

Calidi Biotherapeutics, Inc. issued an amended and restated warrant on May 28, 2026, to an accredited investor, allowing the purchase of up to 17,391,304 unvested common stock shares at an exercise price of $0.23. This amendment modifies a previous warrant from May 6, 2026. Key changes include conditioning the warrant's exercise on stockholder approval, increasing the Minimum Vesting Acquisition Amount from $500,000 to $1,000,000, and extending the Vesting Termination Date to September 30, 2026.

Calidi Biotherapeutics announced that two abstracts highlighting its proprietary RedTail platform have been accepted for online publication at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. The company will present preclinical data on its lead program, CLD-401, a systemically delivered virotherapy, and expects to file an IND for it by the end of 2026. Additionally, preclinical data on CLD-501, an in situ T-cell engager, will be presented, showcasing the platform's ability to deliver genetic medicines to metastatic sites.

Calidi Biotherapeutics announced that its Annual Report on Form 10-K for the year ended December 31, 2025, contained an audit report with an explanatory paragraph. This paragraph emphasized that the consolidated financial statements were prepared assuming the company will continue as a going concern. This disclosure is required by NYSE American Company Guide Section 610(b) and does not reflect any change or amendment to any of the company's filings for the fiscal year ended December 31, 2025.

Calidi Biotherapeutics reported a net loss of $4.11 million for Q1 2026, an improvement from $5.06 million in Q1 2025, with diluted EPS of $(0.43). Despite this, the company disclosed substantial doubt about its ability to continue as a going concern within the next 12 months due to recurring losses and negative cash flows. General and administrative expenses decreased significantly, while research and development expenses slightly increased.

Calidi Biotherapeutics reported a net loss of $4.4 million, or $0.43 per share, for the first quarter of 2026, an improvement from a $5.0 million net loss in the prior year. The company demonstrated a $1.0 million reduction in general and administrative expenses, reflecting a commitment to efficient capital use. Operationally, Calidi presented new data on its CLD-401, RedTail platform, and CLD-501 programs at several major scientific conferences, highlighting profound immune changes and the potential of in situ T-cell engagers. Furthermore, Calidi announced a strategic partnership with TransferAI to streamline the IND submission process for CLD-401, with an IND filing targeted by year-end 2026.

Calidi Biotherapeutics, Inc. issued a warrant on May 6, 2026, to an accredited investor in a private placement. This warrant allows the purchase of up to 17,391,304 shares of common stock at an exercise price of $0.23, becoming first exercisable on September 8, 2026. The warrant's vesting is proportional to potential future issuances of up to $4.0 million in common stock, which may occur prior to July 8, 2026.